Copycat versions of Eli Lilly's diabetes drug Mounjaro and obesity drug Zepbound were supposed to go away this week. They're ...

GLP-1 agonists remain out of reach for many due to high costs, leading some patients to turn to unsafe compounded versions ...

Compounding pharmacies have been allowed to essentially make a cheaper version of Eli Lilly's Zepbound, but they have to stop ...

Large-scale compounding facilities have to stop making tirzepatide, the main ingredient in blockbuster obesity drug Zepbound, Wednesday.

Compounding pharmacy FarmaKeio NM is cementing its role as a crucial part of Winrock Town Center's developing wellness sector. The pharmacy, formerly City Drug, rebranded and relocated to 2100 ...

Compounded GLP-1s have given rise to a cottage industry offering cheaper weight loss medications to many Americans — but now ...

A group of compounding pharmacies has filed a lawsuit against the FDA, challenging the agency’s decision to remove semaglutide — which is used to treat Type 2 diabetes and obesity — from the ...

Many major organizations have publicly opposed the Board’s proposal and are major players in the opposition efforts, including the Alliance for Pharmacy Compounding, Volunteer Fire Foundation ...

and a Texas-based compounding pharmacy operator claims the FDA's finding that there was no longer a shortage of the drugs' active ingredient semaglutide was arbitrary and capricious. The FDA declined ...

WASHINGTON, Feb. 25, 2025 /PRNewswire/ -- A new national poll conducted for the Pharmacy Compounding Foundation by Embold Research shows strong public support for pharmacy compounding's critical ...